Search | Clinical Trials Finder

Conditions: Respiratory Distress Syndrome (Neonatal), Intubation Complication, Death; Neonatal
Interventions: Infasurf Aero™; Combination Product
Lead sponsor: ONY; Industry
Eligibility: 29 Weeks to 36 Weeks
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 10
States / cities: Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 6 more

Conditions: Mediators of Inflammation
Interventions: BMS-986235, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Anaheim, California • Salt Lake City, Utah

Conditions: Pain, Post Operative, Quality of Life
Interventions: Ibuprofen 600 mg, Placebo, Acetaminophen; Drug
Lead sponsor: Marquette University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Sepsis, Septic Shock
Interventions: Vitamin C, Vitamin B1; Drug
Lead sponsor: Trinity Health Of New England; Other
Eligibility: 18 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Cryptosporidiosis
Interventions: Cryptosporidium parvum oocysts (ABO809), EDI048, Placebo; Biological · Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: Arterial Occlusive Diseases, Coronary Artery Disease, Coronary Disease, Arteriosclerosis, Heart Diseases, Myocardial Ischemia, Vascular Diseases, Acute Coronary Syndrome
Interventions: PZ-128, Placebo; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Boston, Massachusetts • Worcester, Massachusetts • Falls Church, Virginia

Conditions: Healthy Participants
Interventions: LY3154207, Placebo, Itraconazole; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: STSA-1002 injection, Placebo; Drug
Lead sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: HIV Infections
Interventions: VH4770359, Placebo, Midazolam; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Adenovirus Disease
Interventions: Brincidofovir, Placebo; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 3 Months to 75 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more

Conditions: Healthy
Interventions: BT-600, BT-600 Placebo; Combination Product
Lead sponsor: Biora Therapeutics, Inc.; Industry
Eligibility: 19 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: T2DM (Type 2 Diabetes Mellitus)
Interventions: Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801; Drug
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Major Depressive Disorder (MDD)
Interventions: amisulpride, placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 159 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Healthy
Interventions: ARRY-371797, p38 inhibitor; oral, Placebo; oral; Drug
Lead sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: single dose NJ-39758979/ matching placebo, multi-dose JNJ-39758979 /matching placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Cypress, California

Conditions: Atopic Dermatitis
Interventions: LEO 138559, LEO 138559 Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder
Interventions: GLYX-13; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Healthy
Interventions: GLPG1205, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cypress, California

Conditions: Fragile X Syndrome
Interventions: Metformin, Placebo oral tablet; Drug
Lead sponsor: Rowan University; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Stratford, New Jersey

Conditions: Overactive Bladder
Interventions: vibegron, Vibegron placebo, Tolterodine Tartrate ER, Tolterodine placebo; Drug
Lead sponsor: Urovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 1,530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 191
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 155 more

Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), or Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Interventions: XXB750, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Inverness, Florida • Jacksonville, Florida • Saint Paul, Minnesota

Conditions: Healthy Volunteer
Interventions: AZD7325, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 50 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Brain Neoplasms
Interventions: Nivolumab, Temozolomide, Radiotherapy, Nivolumab Placebo; Drug · Radiation · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 716 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more

Conditions: Leprosy
Interventions: Tuberculin, Purified Protein Derivative, MLSA-LAM, MLCwA, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Fort Collins, Colorado

Search by objective public record fields.

InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS

A Study of Experimental Medication BMS-986235 in Healthy Subjects

Preemptive Ibuprofen Effects on Pain Perception Following Extraction and Bone Graft

Vitamin C & Thiamine to Treat Sepsis and Septic Shock

Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults

Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention

A Study of LY3154207 in Healthy Participants

The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy Subjects

A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants

Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease

BT-600 Single and Multiple Ascending Oral Doses in Healthy Adult Subjects

A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

The Effects of Dopamine on Reward Processing

A Safety Study of ARRY-371797 in Healthy Subjects

Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male Subjects

Metformin in Patients With Fragile X

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF)

AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects

An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

Leprosy Skin Test Antigens Trial